Marker Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-12.2M | $-10.7M | $-8.2M | $-29.9M | $-41.9M | $-28.7M | $-21.4M | $-148.0M |
| Depreciation & Amortization | — | — | — | $2.8M | $2.1M | $485.6K | $105.1K | — |
| Depreciation | — | — | — | $2.8M | $2.1M | $500.0K | $100.0K | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $537.5K | $245.9K | $858.3K | $3.3M | $6.0M | $5.2M | $5.4M | $16.4M |
| Net Cash from Operating Activities | $-12.0M | $-10.9M | $-16.4M | $-27.0M | $-27.3M | $-20.0M | $-18.3M | $-14.5M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | $375.0K | $147.7K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | $18.7M | $-4.9M | $-3.1M | $-9.3M | $-375.0K | $-147.7K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | $71.7K |
| Net Cash from Financing Activities | $9.9M | $15.0M | $1.1M | $202.1K | $52.6M | $6.7M | $816.5K | $71.2M |
| Net Change in Cash | — | — | — | $11.8M | $43.5M | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | $-18.7M | $-14.6M |